Surf Wiki
Save to docs
general/acetamides

From Surf Wiki (app.surf) — the open knowledge base

Osanetant

Chemical compound

Osanetant

Chemical compound

| elimination_half-life =

Osanetant (developmental code name SR-142,801) is a neurokinin 3 receptor antagonist which was developed by Sanofi-Synthélabo and was being researched for the treatment of schizophrenia but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s.

Professor David J. Anderson, Director and Leadership Chair of the Tianqiao and Chrissy Chen Institute for Neuroscience at California Institute of Technology, has advocated that osanetant be explored as a treatment for pain, anxiety, and aggression in humans and companion animals experiencing bereavement or social isolation, citing research suggesting that osanetant has an excellent safety profile and suppresses negative effects of social isolation in mice through an evolutionarily-conserved mechanism and without acting as a depressant. Another potential application for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.

Osanetant is being investigated by Acer Therapeutics as a treatment for severe vasomotor symptoms such as a hot flashes and flushes among people experiencing menopause.

Synthesis

Several different syntheses have been reported. Below are representative examples.

doi = 10.1016/0960-894X(96)00419-2 }}</ref>

The reaction between 2-(3,4-Dichlorophenyl)-5-(tetrahydropyran-2-yloxy)pentanenitrile (1) and methyl acrylate (2) gives 4-Cyano-4-(3,4-dichlorophenyl)-7-(oxan-2-yloxy)heptanoic aci (3). Treatment with acid gives 3-[3-(3,4-Dichlorophenyl)-2,6-dioxopiperidin-3-yl]propyl acetate, CID:70104936 (4). Reduction of the imide with Borane dimethylsulfide afforded [182621-51-8] (5). The reaction of this intermediate with benzoyl chloride [98-88-4] gives CID:22741724 (6). Treatment with mesyl chloride completed the synthesis of CID:11812710 (7).

doi = 10.1016/S0960-894X(97)00064-4 }}</ref>

The reaction of 1-Benzyl-4-phenyl-4-piperidinol [63843-83-4] (1) with trimethylsilyl cyanide and subsequent Ritter reaction gave N-(1-Benzyl-4-phenylpiperidin-4-yl)formamide, CID:10979305 (2). The reduction of the formamide with lithium aluminium hydride gave 1-benzyl-N-methyl-4-phenylpiperidin-4-amine [172734-03-1] (3). Reaction with acetic anhydride gave CID:22741820 (4). Catalytic hydrogenation removal of the benzyl protecting group gave N-Methyl-N-(4-phenylpiperidin-4-yl)acetamide [172733-87-8] (5).

Convergent synthesis completes the synthesis of Osanetant.

CID:11119744

doi = 10.1021/ml300262e }}</ref>

Subsequent studies have shown that the Osanetant precursor is already a powerful BAT (biogenic amine transporter) substrate without the need for having to surmount the total synthesis of Osanetant. The Ki numbers in the patent for Ex 58 are NET = 2.4nM & DAT = 13.8nM.

This is not the first time that Sanofi produced a 3-arylpiperidine having BAT dopaminergic properties. For example, 3-[3-(Trifluoromethyl)phenyl]piperidine [64321-45-5] was reported in a previous patent. It was stated in the patent that such compounds can be expected to be able to treat depression, obesity, and Parkinson's disease.

References

References

  1. "Osanetant Sanofi-Aventis discontinued, France.". Highbeam.
  2. (July 2001). "Osanetant Sanofi-Synthélabo". Current Opinion in Investigational Drugs.
  3. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor". Life Sciences.
  4. (August 2006). "Tachykinin receptors antagonists: from research to clinic". Current Drug Targets.
  5. (2022-09-12). "Dr. David Anderson: The Biology of Aggression, Mating & Arousal".
  6. (May 2018). "The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress". Cell.
  7. (May 2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology.
  8. (September 2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". The European Journal of Neuroscience.
  9. {{ClinicalTrialsGov. NCT05325775. Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
  10. (October 1996). "A reliable and efficient synthesis of SR 142801.". Bioorganic & Medicinal Chemistry Letters.
  11. "2-(3,4-Dichlorophenyl)-5-(tetrahydropyran-2-yloxy)pentanenitrile". U.S. National Library of Medicine.
  12. "4-Cyano-4-(3,4-dichlorophenyl)-7-(oxan-2-yloxy)heptanoic acid". U.S. National Library of Medicine.
  13. (March 1997). "A practical and scalable synthesis of SR 142801, a tachykinin NK3 antagonist.". Bioorganic & Medicinal Chemistry Letters.
  14. (January 2013). "Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity". ACS Medicinal Chemistry Letters.
  15. "Method for using m-trifluoromethylphenyl-piperidines".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

acetamides antipsychotics benzamides chloroarenes nk3-receptor-antagonists piperidines
Want to explore this topic further?

Ask Mako anything about Osanetant — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report